Analysis Note
These secondary standards offer multi-traceability to the USP, EP and BP primary standards, where they are available.
Biochem/physiol Actions
Paclitaxel is a potent anti-neoplastic and anti-mitotic taxane drug, which binds to the N-terminus of β-tubulin and and stabilizes microtubules arresting the cell cycle at the G2/M phase. The microtubule damage induces apoptosis through a JNK-dependent pathway followed by a JNK-independent pathway, perhaps related to the activation of protein kinase A (PKA) or of Raf-1 kinase, resulting in phosphorylation of Bcl-2. A major metabolite via CYP2CB is 6α-hydroxypaclitaxel (6α-OHP).
Caution
Paclitaxel undergoes transesterification in methanol and hydrolyzes in aqueous solutions.
Footnote
To see an example of a Certificate of Analysis for this material enter LRAA9808 in the Documents slot below. This is an example certificate only and may not be the lot that you receive.
General description
Pharmaceutical secondary standards for application in quality control provide pharma laboratories and manufacturers with a convenient and cost-effective alternative to the preparation of in-house working standards
Other Notes
This Certified Reference Material (CRM) is produced and certified in accordance with ISO 17034 and ISO/IEC 17025. All information regarding the use of this CRM can be found on the certificate of analysis.
This product has met the following criteria to qualify for the following awards: